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Abstract
Objective: To evaluate whether respiratory therapy techniques influence the number of cells within and quantity of induced sputum in 
patients with asthma or chronic obstructive pulmonary disease (COPD). Methods: Randomized clinical trial, in which patients with asthma or 
COPD under intervention (n = 16 and 10, respectively) were compared with control groups (n = 16 and 10). Patients in the asthma/intervention 
(A/I) and COPD/intervention (C/I) groups were submitted to oscillating positive expiratory pressure maneuvers for 5 min, followed by 10 forced 
expiratory technique sequences. These patients were also submitted to an induced sputum protocol with inhaled hypertonic saline (3%, 4% 
or 5%; A/I group) or inhaled isotonic saline (C/I group). The asthma/control (A/C) and COPD/control (C/C) groups were submitted only to the 
standard induced sputum protocol. Results: The final mean weight of the sputum samples was significantly greater in the A/I group than in 
the A/C group (2,767.25 ± 998.08 mg vs. 1,689.17 ± 1,189.96 mg; p = 0.03). The mean/median total cell counts (×106/mL) were higher in 
the A/I and C/I groups than in the A/C and C/C groups (4.06/0.95 and 0.63/0.39, p = 0.05, vs. 5.08/1.77 and 0.64/0.40, p = 0.02). There were 
no statistically significant differences among the groups in terms of cell viability. Conclusions: The use of respiratory therapy techniques can 
increase sputum sample weight in asthma patients, as well as increasing total cell counts in patients with asthma or COPD.
Keywords: Asthma; Pulmonary disease, obstructive chronic; Sputum; Physical therapy modalities.
Resumo
Objetivo: Avaliar se técnicas fisioterápicas interferem no número de células e na quantidade do escarro obtido por coleta induzida, em 
pacientes com asma e doença pulmonar obstrutiva crônica (DPOC). Métodos: Ensaio clínico prospectivo e randomizado, no qual os pacientes 
com asma ou DPOC sob intervenção (n = 16 e 10, respectivamente) foram comparados com grupos controle (n = 16 e 10). Pacientes dos 
grupos asma/intervenção (A/I) e DPOC/intervenção (D/I) foram submetidos a manobras de pressão expiratória positiva oscilante por 5 min, 
seguidas de 10 repetições da técnica de expiração forçada. Além disso, esses pacientes foram submetidos a um protocolo de indução de 
escarro com a inalação de solução salina hipertônica (3%, 4% e 5%), no caso dos A/I, e de solução salina isotônica, no caso dos D/I. Os 
grupos  asma / controle(A/C) e DPOC/controle (D/C) foram somente submetidos ao protocolo padrão de indução de escarro. Resultados: Houve 
aumento significante do peso média final de escarro no grupo A/I vs. grupo A/C (2.767,25 ± 998,08 mg e 1.689,17 ± 1.189,96 mg, 
respectivamente; p = 0,03). O número absoluto de células (×106/mL) foi maior nos grupos A/I e D/I do que nos grupos A/C e D/C 
 ( média / mediana, 4,06/0,95 e 0,63/0,39, respectivamente; p = 0,05; e 5,08/1,77 e 0,64/0,40; p = 0,02). A viabilidade celular não apresentou 
diferença estatisticamente significante entre os grupos. Conclusões: O uso de técnicas respiratórias pode aumentar o peso do escarro em 
pacientes com asma, assim como aumentar o número absoluto de células em pacientes com asma ou DOPC. 
Descritores: Asma; Doença pulmonar obstrutiva crônica; Escarro; Modalidades de fisioterapia.
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Medicine, São Paulo, Brazil, were selected for inclu-
sion in the study. The study was approved by ethics 
in research committee of the institution.
After giving written informed consent, the 
patients who met the following inclusion criteria 
were selected: being 18 years of age or older; having 
no other lung diseases or severe diseases; and being 
able to complete the cough score questionnaire, as 
well as to cooperate with pulmonary function tests 
and procedures for sputum induction/collection. 
The exclusion criteria were as follows: being preg-
nant; currently breastfeeding; being a smoker; using 
supplemental oxygen; being suspected of having 
ischemic heart disease; having recently undergone 
surgery; having a chronic consumptive disease; 
having participated in pulmonary rehabilitation 
programs; being suspected of having steroid-induced 
myopathy; presenting exacerbation of rhinitis; and 
having active gastroesophageal reflux disease.
In this clinical trial, the patients were assigned, 
by random drawing, to one of the two procedures: a 
modified protocol, which consisted in the use of the 
standard protocol in conjunction with two respira-
tory therapy techniques during the procedure; or 
the standard protocol.(7)
The patients were categorized into four 
groups: COPD/intervention; COPD/control; asthma 
intervention; and asthma/control. Each group was 
evaluated in terms of the following variables: age; 
gender; final cough score; forced expiratory volume 
in one second (FEV1); forced vital capacity (FVC); 
FEV1/FVC ratio prior to (for patients with asthma) or 
after (for patients with COPD) the use of bronchodi-
lators; final weight of the sputum samples after 
filtering and dilution; total cell counts (×106/mL); 
cell viability (%); time required to obtain sputum 
samples; peripheral oxygen saturation (SpO2); and 
heart rate (HR).
Before starting sputum induction, the patients 
completed the cough questionnaire(8) on daytime 
and nighttime symptoms. The questionnaire was 
administered by the researcher, and the maximum 
score for each symptom was five points.
All patients underwent evaluation of pulmonary 
function using spirometry, which was conducted in 
accordance with the Second Brazilian Consensus on 
Spirometry (2002).(9) Prebronchodilator and post-
bronchodilator FVC, FEV1 and FVC/FEV1 values 
were determined using a Koko pneumotachograph 
and the accompanying PFT software program for 
Introduction
Chronic inflammatory diseases with airflow 
limitation, bronchial hyperresponsiveness and 
inflammation cause dyspnea, cough and wheezing, 
which are considered nonspecific respiratory symp-
toms. Airway diseases can be evaluated by spirometry, 
as well as by measuring peak expiratory flow and 
bronchial responsiveness.(1) In addition, some objec-
tive measurements can be used to evaluate the 
relationship between the alterations observed in 
ventilatory function and airway inflammation.
The analysis of induced sputum samples can 
contribute to the evaluation of this inflammatory 
process by allowing the characterization of cells and 
cytokines. The induced sputum technique represents 
a valid, viable, reproducible and minimally invasive 
tool.(2) However, it can be difficult to obtain sputum 
samples from patients with stable asthma as well 
as from certain patients with chronic obstructive 
pulmonary disease (COPD).
It is known that respiratory therapy, through 
the use of specific techniques and maneuvers, can 
promote mucus clearance.(3) In addition, respiratory 
therapy maneuvers, such as therapy with oscillating 
positive expiratory pressure (OPEP) and the forced 
expiratory technique (FET) or huffing, are used for 
secretion displacement and expectoration in patients 
with airway hypersecretion.(3) These two respiratory 
therapy techniques are routinely recommended for 
the bronchial hygiene of patients with hypersecre-
tion and are typically successful.(3,4) However, there 
is no evidence that respiratory therapy techniques 
can be adjunct tools in sputum collection for the 
analysis of the inflammatory process. Therefore, the 
objective of this study was to evaluate whether these 
respiratory therapy techniques influence the quan-
tity of and number of cells within induced sputum 
in patients with asthma or COPD, with or without 
hypersecretion.
Methods
Individuals with stable asthma, defined based on 
the Guidelines for the Diagnosis and Management of 
Asthma Update on Selected Topics,(5) and individuals 
with COPD (classified as stage III), according to the 
Global Initiative for Chronic Obstructive Lung Disease 
criteria,(6) all treated at the Pulmonology Outpatient 
Clinic of the Department of Medicine of the São Paulo 
Hospital, Federal University of São Paulo School of 
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20 to 25 cmH2O and from 0.8 to 2.5 cmH2O, respec-
tively.(10,11) At the end of the process, the patients 
were instructed to stimulate expectoration through 
efficacious coughing.
The FET or huffing consists of one or two 
expiratory efforts (huffs), similar to those carried 
out during peak expiratory flow measurement, 
performed with an open glottis. A forced expiratory 
maneuver at medium lung volume until reaching low 
lung volume was required, followed by a relaxation 
period, preferably with diaphragmatic breathing.(4) 
The patients, maintained in a sitting position, were 
advised to expel the sputum through efficacious 
coughing after the FET maneuver.
Induced sputum collection: modified protocol
Sputum collection was performed using an 
induction method previously described.(7) The 
patients were monitored throughout the protocol 
period using a portable pulse oximeter (model 
9500; Nonin Medical Inc., Minneapolis, MN, USA) 
to determine SpO2 and HR.
In order to induce sputum, the patients received 
9 mL of inhaled hypertonic saline at 3% (a higher 
concentration, maximum of 5%, was used if neces-
sary) for 7 min by means of an ultrasonic nebulizer 
(DeVilbiss, Somerset, PA, USA). Subsequently, 
Windows, version 4.1 (PDS Instrumentation, Inc., 
Louisville, CO, USA). After evaluation of pulmonary 
function, the patients were instructed to perform 
nasal and oral hygiene, as well as to drink water, in 
preparation for the subsequent initiation of sputum 
induction and collection.
The OPEP can be applied using a pipe-shaped 
mucus clearance device (Flutter®; Scandipharm, 
Birmingham, AL, USA). The Flutter is a portable 
device containing a conical channel, within which 
there is a metallic sphere. When the patient exhales 
through the device, the expired airflow raises the 
metallic sphere, which falls again under its own 
weight. The rapid succession of these events (risings 
and fallings of the sphere) makes the air vibrate 
within the device. This vibration is transmitted to 
the patient rib cage and tracheobronchial tree, 
displacing the secretions and facilitating expectora-
tion. Therefore, this device uses the force of gravity 
to increase or decrease positive pressure. The patients 
were instructed to use the device while sitting and 
to hold it firmly, maintaining the mouthpiece 
horizontal. Lips around the mouthpiece and main-
taining the device horizontal, patients performed a 
deep (unforced) inhalation through the nose and an 
exhalation through the mouth. During this process, 
maximal and minimal airway pressure ranges from 
Table 1 - Characteristics of the patients studied.
Clinical variable Asthma/intervention Asthma/control p
n 16 16 -
Agea, years 43.31 ± 13.81 43.69 ± 16.60 0.95*
Gender, F/M 9/6 10/7 1.00**
Pre-BD FEV1
a, L 2.30 ± 0.68 2.10 ± 0.70 0.42*
Pre-BD FVCa, L 3.46 ± 0.79 3.24 ± 0.96 0.48*
Pre-BD FVC/FEV1
a 66.50 ± 12.89 64.90 ± 9.95 0.70*
Post-BD FEV1
a, L 2.45 ± 0.68 2.43 ± 0.74 0.94*
Post-BD FVCa, L 3.62 ± 0.70 3.48 ± 1.07 0.68*
Post-BD FVC/FEV1
a 67.56 ± 12.47 70.29 ± 9.70 0.50*
Clinical variable COPD/intervention COPD/control p
n 10 10 -
Agea, years 66.00 ± 6.46 63.70 ±7.21 0.46*
Gender, M/F 1/9 1/9 1.00**
Post-BD FEV1
a, L 1.30 ± 0.36 1.54 ± 0.63 0.32*
Post-BD FVCa, L 2.71 ±0.80 3.13 ± 0.85 0.27*
Post-BD FVC/FEV1
a 49.10 ± 7.72 47.90 ± 9.39 0.76*
FEV1: forced expiratory volume in one second; BD: bronchodilator; FVC: forced vital capacity; FVC/FEV1: FVC/FEV1 ratio, and 
COPD: chronic obstructive pulmonary disease.aValues expressed as mean and standard deviation. *Chi-square test; and **Student’s 
t-test.
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saline concentration was used only in the group of 
patients with asthma, since, in the group of patients 
with COPD, the saline concentration, in the succes-
sive inhalations, was fixed at 0.9%.
The interval between the performance of each 
respiratory therapy technique and the production of 
the sputum sample was timed: after the first inha-
lation of saline solution and OPEP, 15 min; after 
the first FET, 20 min; after the second inhalation, 
30 min; after the second OPEP, 35 min; after the 
second FET, 40 min; after the third inhalation, 
50 min; after the third OPEP, 55 min; and after the 
third FET, 60 min. The maximum time was 60 min.
The material was processed by an experienced 
laboratory technician, who was blinded to the 
protocol performed to obtain sputum samples. This 
procedure was started within the first 2 h, as recom-
mended by some authors.(7,12,13)
After the expectorated material had been 
collected, the patients were observed clinically for a 
minimum of 30 min.
Induced sputum collection and processing: 
standard protocol
The procedures for collecting and processing 
the material were performed using a method previ-
ously described.(7,12,13) Although the induced sputum 
protocol was identical to that previously presented, 
the respiratory therapy techniques described above 
were not employed.
Statistical analysis
The variables were presented as mean and 
standard deviation values for parametric data, as 
the patient, sitting straight and maintaining the 
device horizontal, was instructed to make calm but 
prolonged exhalations for 5 consecutive min, using 
OPEP maneuvers. The patient was asked to cough 
vigorously, subsequently expectorating in a dispos-
able collection container. This expectorated material 
was placed in a disposable Petri dish, where it was 
evaluated, and the procedure was interrupted when 
the weight of the thickest or most viscous portion 
of the sputum sample was equal to or greater 
than 100 mg, the event being considered positive. 
Weight was measured using an analytical precision 
scale (Gehaka, São Paulo, Brazil). This material was 
then processed (dilutions and filtering), according 
to the technique described by other authors,(7,12,13) 
and weighed again, this being considered its final 
weight. If the expectorated material, after the 
maneuver using the device, was not considered satis-
factory, FET was performed. The FET consisted of 
10 expiratory maneuvers at 30-s intervals, followed 
by vigorous cough and expectoration. If the quantity 
of material obtained was satisfactory, the procedure 
was interrupted. Otherwise, 4% saline was admin-
istered via inhalation, and the entire procedure 
described previously was repeated. This continued, 
with successive concentrations of inhaled saline 
(maximum, 5%). The test was considered a negative 
event if, in the final phase, the patient could not 
expectorate the necessary quantity.
After each inhalation, FEV1 was measured. If there 
was a greater than 20% decrease in FEV1, sputum 
induction was interrupted. If the decrease in FEV1 
was between 10% and 20%, the saline concentra-
tion used in the last inhalation was maintained. It is 
important to emphasize that sequential variation in 
Table 2 - Sputum sample weight, cell viability and total cell counts in the groups studied.
Variable studied Asthma/intervention Asthma/control p
n 12 12
Sample weighta, mg 2.767.25 ± 998.08 1.689.17 ± 1.189.96 0.03*
Total cell countsb, ×106/mL 4.06 (0.95) 0.63 (0.39) 0.05**
Cell viabilityb, % 56.00 (59.00) 43.17 (48.50) 0.10*
Variable studied COPD/intervention COPD/control p
n 10 10
Sample weighta, mg 3.457.10 ± 1.721.29 2.805.20 ± 1.752.28 0.41*
Total cell countsb, ×106/mL 5.08 (1.77) 0.64 (0.40) 0.02**
Cell viabilityb, % 67.30 (69.50) 58.80 (55.50) 0.23**
COPD: chronic obstructive pulmonary disease. aValues expressed as mean ± SD; and bvalues expressed as mean (median). *Student’s 
t-test; and **Mann-Whitney test.
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producing an adequate quantity of sputum. The time 
required to obtain sputum samples was significantly 
shorter in the COPD group (p < 0.0001; Figure 1).
Discussion
In the present study, we demonstrated that 
OPEP and FET were efficient in inducing sputum 
for collection, increasing the final weight of the 
material expectorated by the patients with asthma.
In the literature, there are no studies describing 
associations between respiratory therapy techniques 
and increased total cell counts in induced sputum 
protocols. In our study, we observed a statistically 
significant postintervention increase in total sputum 
cell counts in the asthma group and in the COPD 
group (Table 2).
We also observed that the respiratory therapy 
maneuvers did not influence sputum cell viability.
The patients included in our study were fully 
comparable to the controls in terms of gender, age 
and pulmonary function, demonstrating the validity 
of the results observed (Table 1).
The pulmonary function profile was more severe 
in the patients with COPD, who presented lower 
median for nonparametric data and as percentages 
for categorical data. Numerical independent vari-
ables were compared using the unpaired Student’s 
t-test. Preintervention and postintervention data 
were analyzed using the paired Student’s t test.
Spearman’s correlation coefficient was used 
to analyze how well the time required to obtain 
sputum samples correlated with cell viability and 
with total cell counts.
In order to compare the time required to obtain 
sputum samples from patients under interven-
tion (asthma/intervention and COPD/intervention 
groups), Kaplan-Meier curves were generated. In 
those curves, the event was defined as obtaining 
an adequate quantity of sputum. The log-rank test 
was used in the analysis of the significance of the 
curves obtained.
The level of statistical significance required to 
reject the null hypothesis was set at p < 0.05.
Results
In this prospective and randomized clinical trial, 
52 patients were studied. Of those, 32 had asthma 
(16 in the intervention group and 16 in the control 
group) and 20 had COPD (10 in the intervention 
group and 10 in the control group). All COPD 
patients were successful in producing an adequate 
quantity of sputum for analysis, whereas only 75% 
of the patients with asthma produced a quantity of 
sputum sufficient for analysis. None of the patients 
included in the study presented a greater than 20% 
decrease in FEV1 during any of the study phases.
Table 1 presents the characteristics of the 
patients studied.
Daytime and nighttime cough scores were lower 
in the patients with asthma than in the patients 
with COPD (median values, 1 and 2, respectively; 
p < 0.01).
Table 2 presents the results regarding final 
sputum sample weight, total cell counts and cell 
viability in the patients studied.
There was no correlation between cell viability 
and total cell counts over time with the use of the 
techniques in the groups.
Using the Kaplan-Meier curves, we observed 
that all patients with COPD managed to expecto-
rate adequately within the first 20 min of study. 
However, among the patients with asthma, 4 (25%) 
reached the end of the intervention (60 min) without 
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Figure 1 - Analysis of the Kaplan-Meier curves generated 
by comparing the time required to obtain sputum samples 
from patients with asthma and patients with chronic 
obstructive pulmonary disease (COPD) using the *log-rank 
test (event # = adequate quantity of sputum).
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drainage and thoracic percussion) were used, were 
compared with patients in whom only OPEP was 
used. The quantity of sputum was found to be 
significantly increased in the two groups studied. 
In our study, the COPD group was expected to 
present a greater quantity of sputum and a better 
response to the stimuli provided by the respira-
tory therapy techniques, since this group presents 
bronchial hypersecretion, as well as higher daytime 
and nighttime cough scores. However, there was no 
statistically significant difference in terms of the 
weight or viability of the material.
Other authors,(19) in a study involving in patients 
with chronic bronchitis, compared the effects of 
postural drainage, OPEP (using the Flutter device), 
and slow exhalation with an open glottis in the 
lateral decubitus position. The authors observed an 
increase in sputum production, obtained 30 min 
after the intervention, for all of the respiratory 
therapy techniques evaluated. The increase in 
sputum production was more significant when the 
OPEP technique was used. In our study, the mean 
interval between the performance of an interven-
tion and the production of a sputum sample was 
shorter in the patients with COPD (20 min) than in 
the patients with asthma (Figure 1).
The inclusion of the two respiratory therapy 
techniques in an induced sputum protocol was effi-
cient in terms of increasing final sputum sample 
weight in patients with asthma, also increasing total 
inflammatory cell counts for the analysis of the 
samples from patients with asthma or COPD. This 
represented an improvement in the induced sputum 
method conventionally used, since some induced 
sputum tests are excluded due to the small volume 
of material obtained. During the study period, there 
were no episodes of bronchospasm, nor were there 
any alterations in SpO2 or HR.
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